An update to the British Association of Dermatologists 2005 guidelines for biologic interventions for psoriasis was published. The interventions reviewed comprised infliximab, etanercept, adalimumab and ustekinumab. The guidelines discuss definitions of response, eligibility criteria, efficacy, drug combinations, adverse effects and toxicity, pretreatment assessments, and monitoring and transitioning of therapies. Indications for drug cessation and audit points are also reviewed (Smith, C.H. et al. Br J Dermatol 2009, 161: 987).